Novel, selective, orally active small molecule antagonists (and agonists) of the human protease-activated receptor 2 (PAR2) have been developed for the potential treatment of inflammatory diseases, metabolic syndrome and cancer.

Key Features

  • Novel small molecules
  • Orally active
  • Effective in models of acute and chronic inflammation, IBD and obesity
  • Selective and potent
  • Novel target and unique mechanism of action.

Back to available technologies

Contact us

To enquire about this Available Technology, please contact us.